Injectable Drug Delivery (IDD) System Provides Improved Patient Experience

24 November 2020: The injectable drug delivery (IDD) market is expected to witness considerable growth on account of increasing need for drug delivery systems and rising instances of chronic diseases like diabetes and cancer. Injectables are used for the treatment of diseases such as cystic fibrosis, Wilson’s disease, autoimmune diseases, hemophilia, hepatitis C, etc. as they offer a faster course of action. Comatose and unconscious patients are administered these drugs over other modes of drug delivery.

 
Due to the effectiveness and speed of delivery, the target injectable drug delivery system provides improved patient experience and is one of the most effective routes of administration. The advancements in technology are promoting the global injectable drug delivery market. With regulatory government norms, there is a greater emphasis on companies to stay updated with the latest developments in order to mitigate the challenges within the industry and remain compliant to gain the edge over competitors.

R&D Investments Boost Drug Delivery System

On the basis of product, the injectable drug delivery market is segmented into formulations and devices. Conventional injection devices and self-injection devices are two segments of devices. Devices that are designed for self-injection include auto-injectors, pen-injectors, needle-free injectors, and others.

On the basis of formulations, the injectable drug delivery market is categorized into conventional drug delivery, novel drug delivery, and others. The conventional drug delivery systems include emulsions, reconstituted lyophilized formulations, solutions, and suspensions. Novel drug delivery systems include colloidal dispersions, which are niosomes, liposomes, mixed micelles, polymeric, and nanoparticles. Microparticles are designed specifically for the rapid absorption of the drug at the target location. Use of colloidal dispersions in the drug delivery systems has been rising significantly owing to rising investments by manufacturing companies in their R&D.

The fastest gaining segment of the injectable drug delivery market includes devices that are mostly self-injection devices. At the primary level, the usage of these devices promote the control and management of various disorders. 

Market Insights
The increasing instances of diabetes and cancer in recent years and rising use of injectable drugs in their treatment and the current trends in developing safety syringes, prefilled syringes, and auto-injectors are amplifying the market growth. 

In order to ease their manufacturing and distribution processes, major companies in the market have entered into consolidated partnerships for certain products. Leading companies in the injectable drug delivery market include like Baxter International, Inc.; Pfizer, Inc.; Becton; Terumo Corporation; Schott AG; Dickinson and Company; and among others.

Innovations of New Products to Boost Demand For Orthobiologics

28 July 2020: Orthobiologics, also termed as regenerative cellular treatments, are components that orthopedic specialists use to recover injuries more rapidly. Orthobiologics are used to recover the healing of injured muscles, broken bones, ligaments, and tendons. These products are made from constituents that are naturally found in your body. 

Orthobiologics associated products comprise development factors that frequently secrete growth factors to recover pain, help rebuild the normal functioning, and facilitate tissue healing. These orthobiologics also have application for the treatment of situations such as spinal fusion and fracture recovery There are several categories of orthobiologics present in the industry, which depend on the various mechanism of actions.  

Viscosupplementation Product Segment to Dominate in the Forecast Period

On the basis of product, the orthobiologics market can be classified into viscosupplementation, bone morphogenetic protein (BMP), demineralized bone matrix (DBM), stem cell therapy, synthetic bone substitutes, and allograft. High demand for viscosupplementation will lead to high adoption rate thereby boosting the segment.

The dominant share of the orthobiologics is attributed to high acceptance of these products because of widespread availability and unprecedented approval in diseases such as hip degenerative joint disease and osteoarthritis. In addition, the large share of product segment is attributed to lower cost of viscosupplementations and increasing occurrence of osteoarthritis of the hip and knee joints among the geriatric populace. 

The high acceptance rate is supposed to be a significant advantage related to viscosupplementation. These advantages comprise reduced pain, better knee movement, fewer side effects, and relatively lesser invasive in nature. It is also supposed to be an outcome of extensive demand for minimally invasive operational procedures leading to high adoption by the patient populace base.

Spinal Fusion Accounted for Majority Share in the Application Segment

The major application variants of the orthobiologics include reconstructive surgery, trauma repair, and spinal fusion. The spinal fusion sector accounted for more than half of the market share and is anticipated to expand at the fastest CAGR in the forthcoming period. 

The growth of spinal infusion is attributed to demineralized bone matrices, constant saturation of bone morphogenetic proteins, and allografts and autografts in spinal fusion surgeries on account of its ability to offer rapid bone healing and high bone stability thereby improving long-term spinal diseases. Reduced hospital visits and stay duration and the fast stimulus of cells to start bone formation are the other benefits of orthobiological products in spinal fusion. 

Hospitals Segment to have a Dominant Share in the End User Segment

On the basis of the end user, the orthobiologics can be classified into orthopedic clinics and hospitals. The hospital's sector accounted for the dominant share in the end user segment and is anticipated to expand at the fastest CAGR in the forthcoming period. 

Increasing acceptance of orthobiological products in reconstructive and spinal surgeries performed in hospitals is a major factor attributed to the growth of the segment in the forecast period. Furthermore, the easy availability of a wide range of orthobiologics in hospitals and specialized patient care is likely to boost the demand for the market in the forecast period. 

Additionally, frequent re-admissions, large procedure volumes, and high patient turnaround are contributing to the segment growth. Also, the supportive infrastructure facilities exact operative methods is further estimated to raise the growth potential of the segment in the years to come.

Market Insights:

The key companies include new product growth activities, distribution improvement strategies, and collaborations, frequent product approval and mergers & acquisitions. In May 2016, NuVasive Inc. introduced AttraX Putty, the next generation biologics technology, which is an artificial bone graft, designated in posterolateral spinal surgery, as an autograft extender. This introduction of the product was carried out to gain an advantage and increase the product range over the market players. 

Medtronic is one of the topmost global players in the orthobiologics market on account of the rapid successful launch and fast acceptance for Infuse bone morphogenetic protein. This company is anticipated to withstand the highest share in the years to come on account of the robust sales force for Infuse and higher cost and FDA support received for the use of Infuse in new spine surgery indication in April 2018. 

Leading players operating in the orthobiologics market include Smith & Nephew plc; Medtronic; Stryker Corporation; Genzyme; and DePuy Synthes, Inc.

Bioinformatics Improves Drug Discovery Process thus increasing the Demand

16 June 2020: Bioinformatics is an integrative field that develops software and systems tools for understanding the biological data. It mainly combines biology, computer science, mathematics, statistics, and information engineering to understand and examine biological data. The recognition of candidate genes and single nucleotide polymorphisms (SNPs) are the most common uses of bioinformatics. In the past years, the scope of bioinformatics has extended significantly. Bioinformatics also tries to understand the structural principles within the nucleic acid and protein sequences, which are stated as proteomics.

Bio-Content Processing and Management Sector Accounted for the Largest Share in the Market 

The major product variants of the bioinformatics market include bio-content processing and management, and genetic sequence platform. The bio-content processing and management sector accounted for the largest share in the market and is anticipated to expand at the fastest CAGR in the forthcoming period. The factors such as high usage rates of bioinformatics software and tools in database management is the primary reason attributing towards its large share in the bioinformatics in the years to come. 

On the other hand, the genetic sequence platform are anticipated to witness a high revenue share in the years to come. The factors attributed to the growth of genetic sequence platform segment include increasing demand for exome and genome sequencing technologies as a result of decreasing prices of genetic sequencing. In addition, there have been numerous developments in genomic technology that have given rise to substantial improvements in availability of predication tools for secondary and tertiary structures of proteins and other biomolecules. 

Expected development of imagining softwares used for high performance sequence examination comprising protein annotation, and DNA sequences, is also a factor anticipated to boost the bioinformatics growth over the forthcoming period. 

Market Insights: 

The key companies are involved in RNA sequencing capabilities to further decrease the prices of genome sequencing. The development of next generation sequencing technologies is anticipated to propel the bioinformatics industry in the forecast period. For example, in January 2018, Thermo Fisher Scientific announced Ion Gene Studio S5 Series, a line of extremely adaptable next generation sequencers. 

Leading players operating in the bioinformatics market include BIOVIA; IBM Life Sciences; Life Technologies Corporation; 3rd Millennium Inc.; Agilent technologies; Celera Corporation; Bio Wisdom Ltd.; Rosetta Bio software; and Affymetrix.

DNA & Gene Chip Promotes Research on Providing Genomic Information

7 May 2020: The DNA & gene chip market is expected to grow due to its ability to provide high throughput capabilities for comprehensive genome studies. It underlines the importance of the DNA microarray technology and has helped in gaining insights on various diseases. Large numbers of nucleic acid fragments can be analyzed using DNA microarray technology in a single experiment. In order to further enhance reliability of this technology, continuous development of new tools is required, which is likely to drive this market in coming years. 

Microarray to Assist in Gene Studies

Based on products, consumables held the largest share in the DNA & gene chip market in 2017 and the segment is likely to grow over the forecast period. Due to availability of reagents and technological advancements along with availability of ancillary components the gene expression data analysis algorithms is becoming easy to implement a microarray procedure. 

Instruments segment in the microarrays are anticipating exponential growth of DNA & gene chip over the forecast period due to introduction of new instruments that are proving assistance in gene. For instance, in November 2016, for the purpose of diagnostic and research, Applied Micro Arrays announced Innopsys range of microarray scanners.

There has been a growing need for solutions to classify vast information into a usable form that has occurred due to massive DNA sequence information generated by the Human Genome Project and gene expression studies. The DNA & gene chip technology provides speeding clinical utility of genomic information efficiently aiding in creating public databases.

High demand for applications of DNA & gene chip microarrays in biomedicine has resulted in manufacturers; increasing inclination towards development of novel solutions for analysis and storage of microarray-generated data. 

Market Insights

The growth of this technology is due to characteristics of DNA & gene chip microarrays to analyze genes. Demand in clinical laboratories along with advancements in method of fabrication, robotics, and computational capabilities for microarrays have fueled the market growth. 

Research collaborations are helping the technology gain more grounds in genomics. For instance, in February 2016, Illumina, Inc. signed agreements for biobanking with Montreal Heart Institute, Partners HealthCare, University of Colorado, and Vanderbilt University. 

Some of the major players of the DNA & gene chip market are Microarrays Inc; Agilent Technologies; Thermo Fisher Scientific, Inc. (Affymetrix, Inc.); CapitalBio Corporation, Perkin Elmer, Inc.; Illumina, Inc.; Asper Biotech; Arrayit Corporation; Macrogen Inc.; and Greiner Bio One International GmbH.

Genomics Provides Innovative Solutions for Disease Management

28 April 2020: The genomics market has witnessed significant growth due to research activities carried out to supply genomic data pool for biologists, patients, and physicians to further investigate certain diseases. Genomics is a study of genomes and its interaction with a different types stimuli. The field has received extensive attention in terms of research and development over the years. It has also witnessed a significant rise in technologies that use research results to understand the role played by genomes in the growth and survival of all organisms. 

Innovation in Analysis to Boost Pharmaceutical Industry

Based on application and technology the market can be classified into functional, epigenomics, pathway analysis, biomarker discovery, and others. Generation of large amount of data sequencing has led to the growth of the segment. Development of advanced technologies has promoted the expansion of gene studies, which has further propelled the segment growth. Integration of functional genomics with innovative solutions has led to new scope for the development of drugs with minimum side effects. 

Within the molecular networks, individual targets are investigated to understand the functioning of biological processes at cellular level. Behavioral genetic tool kits can evaluate competing hypotheses regarding particular behavior. Pathway analysis for drug development and in life sciences help improve understanding of molecular biology and cellular biology. On the other hand, next-generation therapeutics is a preferred choice of the pharmaceutical companies for network analysis.

Pathway-based analysis has gained more attention after the emergence of genomics and personalized therapies. The information on disease network gained through pathway analysis is used to address the challenges faced in developing therapeutics. Pathway analysis includes gene annotation databases and gene ontology.

Market Insights

Advancements in personalized medicine and genomics has led to vast exploration and research in disease management boosting growth of the market. Implementation of genetic studies in consumer wellness programs and population screening and other several health programs in order to optimize preventive care for diseases will propel growth of the industry.

For instance, in March 2019, Oxford Nanopore launched Flongle starter packs which conducts an on-demand DNA or RNA sequencing tests. It has a potential to offer rapid insights at low cost. It provides analysis of any living thing and can be done by anybody at any place.  It can be used in scientific laboratories, in farms, in industries and factories, outdoor environments, healthcare settings, or in classrooms.

Major companies of the genomics market include Agilent Technologies; Foundation Medicine, Inc., Thermo Fisher Scientific, Inc.; Danaher; 23andMe, Inc., Oxford Nanopore Technologies.; Illumina, Inc.; Bio-Rad Laboratories, Inc.; F. Hoffmann-La Roche Ltd.; BGI; Pacific Biosciences; and Myriad Genetics, Inc.

Innovations of New Products to Boost Demand For Orthobiologics

7th April 2020: Orthobiologics, also termed as regenerative cellular treatments, are components that orthopedic specialists use to recover injuries more rapidly. Orthobiologics are used to recover the healing of injured muscles, broken bones, ligaments, and tendons. These products are made from constituents that are naturally found in your body. 

Orthobiologics associated products comprise development factors that frequently secrete growth factors to recover pain, help rebuild the normal functioning, and facilitate tissue healing. These orthobiologics also have application for the treatment of situations such as spinal fusion and fracture recovery There are several categories of orthobiologics present in the industry, which depend on the various mechanism of actions.  

Viscosupplementation Product Segment to Dominate in the Forecast Period

On the basis of product, the orthobiologics market can be classified into viscosupplementation, bone morphogenetic protein (BMP), demineralized bone matrix (DBM), stem cell therapy, synthetic bone substitutes, and allograft. High demand for viscosupplementation will lead to high adoption rate thereby boosting the segment.

The dominant share of the orthobiologics is attributed to high acceptance of these products because of widespread availability and unprecedented approval in diseases such as hip degenerative joint disease and osteoarthritis. In addition, the large share of product segment is attributed to lower cost of viscosupplementations and increasing occurrence of osteoarthritis of the hip and knee joints among the geriatric populace. 

The high acceptance rate is supposed to be a significant advantage related to viscosupplementation. These advantages comprise reduced pain, better knee movement, fewer side effects, and relatively lesser invasive in nature. It is also supposed to be an outcome of extensive demand for minimally invasive operational procedures leading to high adoption by the patient populace base.

Spinal Fusion Accounted for Majority Share in the Application Segment.

The major application variants of the orthobiologics include reconstructive surgery, trauma repair, and spinal fusion. The spinal fusion sector accounted for more than half of the market share and is anticipated to expand at the fastest CAGR in the forthcoming period. 

The growth of spinal infusion is attributed to demineralized bone matrices, constant saturation of bone morphogenetic proteins, and allografts and autografts in spinal fusion surgeries on account of its ability to offer rapid bone healing and high bone stability thereby improving long-term spinal diseases. Reduced hospital visits and stay duration and the fast stimulus of cells to start bone formation are the other benefits of orthobiological products in spinal fusion. 

Hospitals Segment to have a Dominant Share in the End User Segment

On the basis of the end user, the orthobiologics can be classified into orthopedic clinics and hospitals. The hospital's sector accounted for the dominant share in the end user segment and is anticipated to expand at the fastest CAGR in the forthcoming period. 

Increasing acceptance of orthobiological products in reconstructive and spinal surgeries performed in hospitals is a major factor attributed to the growth of the segment in the forecast period. Furthermore, the easy availability of a wide range of orthobiologics in hospitals and specialized patient care is likely to boost the demand for the market in the forecast period. 

Additionally, frequent re-admissions, large procedure volumes, and high patient turnaround are contributing to the segment growth. Also, the supportive infrastructure facilities exact operative methods is further estimated to raise the growth potential of the segment in the years to come.

Market Insights:

The key companies include new product growth activities, distribution improvement strategies, and collaborations, frequent product approval and mergers & acquisitions. In May 2016, NuVasive Inc. introduced AttraX Putty, the next generation biologics technology, which is an artificial bone graft, designated in posterolateral spinal surgery, as an autograft extender. This introduction of the product was carried out to gain an advantage and increase the product range over the market players. 

Medtronic is one of the topmost global players in the orthobiologics market on account of the rapid successful launch and fast acceptance for Infuse bone morphogenetic protein. This company is anticipated to withstand the highest share in the years to come on account of the robust sales force for Infuse and higher cost and FDA support received for the use of Infuse in new spine surgery indication in April 2018. 

Leading players operating in the orthobiologics market include Smith & Nephew plc; Medtronic; Stryker Corporation; Genzyme; and DePuy Synthes, Inc.

Technological Advancement in Genotyping to Boost Market Growth

26 March 2020: Genotyping is a technique used to detect genetic alteration in the allelic genes or genomic sequence of an individual by associating it against the reference sequence. It assists to explore genetic variants including single nucleotide polymorphism (SNPs) and structural changes in DNA.

The emerging trend in the market is technological advancement of including chips that adjust 1 million SNP assays and other developments that resulted in identification of numerous novel genes for the common diseases.

Reagents and Kits Segment to Contribute Significant Demand to the Market

The major product variants of the genotyping market include services, reagents and kits, and instruments. The reagents and kits sector accounted for the fastest growing sector in the market and is anticipated to expand at a CAGR of 23.0% over the forthcoming period. 

The factors that attribute to the growth of genotyping industry include extensive usage rate and constantly increasing demand for the genotyping tests. The easy availability and cost-effectiveness of the reagents are anticipated to significantly influence the market growth in the forecast period.

In addition, the presence of favorable funding programs and extensive application in the R&D laboratories are expected to further propel the reagents and kits segment in the years to come. Reagents, such as enzymes, buffers, and assays are extensively used for PCR cleanup, cellular manipulation, and DNA sequencing. The introduction of new reagents, such as SBE and ExoSAP-IT PCR products, and PCR cleanup reagents by Affymetrix, Inc., is also expected to observe a high acceptance rate over the forecast period.

Market Insights

Mergers, acquisitions, and collaborations are the key market strategies undertaken by the companies to support their global presence. For example, in December 2015, Thermo Fisher, Inc. purchased Life Technologies Corporation with the purpose of growing its product portfolio for the genotyping industry. 

In April 2016, a strategic collaboration was announced by Siemens Healthcare GmbH and Thermo Fisher Scientific, Inc. for the growth of an innovative and integrated genotyping platform. This contract is expected to present improved customizability and flexibility to their molecular testing solutions.

Leading players operating in the genotyping market include Agilent Technologies, Inc; Affymetrix, Inc.; Fluidigm Corporation; Genewiz, Inc.; Illumina, Inc.; GE Healthcare GmbH; Qiagen NV; Roche Diagnostics; and Thermo Fisher Scientific, Inc.

Next Generation Sequencing (NGS) to Offer Precision Treatment

19th March 2020: The Next Generation Sequencing (NGS) market is expected to grow due to high demand for precision treatment, genomics research, and clinical diagnosis of varied diseases. NSG enables rapid sequencing of the base pairs in RNA or DNA samples. It is also used for various applications, such as chromosome counting, gene expression profiling, molecular analysis, and detection of epigenetic changes and has enabled innovation and discovery in personalized medicine.  

NSG Services promote treatment and diagnosis of rare diseases

Based on products and services the NGS platforms and products accounted for the largest share of the market in 2018. The segment comprises of software and instruments that are used for preparation of samples, libraries, and sequencing. The most widely used NGS products include Illumina’s MiniSeq, MiSeq, and NextSeq, Thermo Fisher’s Ion Proton System, Ion PGM, and Ion GeneStudio S5 NGS system. MiniSeq, offers cost-efficient sequencing, streamlined workflow enabling sequencing, and ancillary equipment and provides scientists and engineers with training, and support, through data analysis.

On the other hand, the NGS services segment is anticipating growth during the forecast period (2019 - 2025). Key companies such as Roche; Illumina, Inc.; and Pacific Biosciences, offer various services to assist the researchers and promote development personalized medicines, genomic sequences, and in the diagnosis of rare diseases.

Market insight

Increasing applications of NGS along with its affordable cost and accuracy with other advantages such as drug discovery are likely to boost the growth of the market. The development of personalized medicine offers new scope accelerating the market growth. Difficulty of data handling and other issues associated with Big Data management are concerns that hamper the growth of the market.

Biotech industries are making investments in order to cure diseases using the NGS to develop advanced diagnostic kits. Major companies of the market are also keen on promoting new product development initiatives along other strategies such as M&A to strengthen their position in the market. For instance, Edico Genome was acquired by Illumina to improve the overall efficiency of NGS solutions. Key companies in the next generation sequencing (NSG) market include Eurofins GATC Biotech GmbH; Oxford Nanopore Technologies; Thermo Fisher Scientific, Inc.; BGI; PierianDx, Inc.; Perkin Elmer, Inc.; F Hoffman-La Roche Ltd.; Genomatix GmbH; Illumina Inc.; DNASTAR, Inc.; QIAGEN; and Bio-Rad Laboratories, Inc.

Introduction of Novel Technologies Fuels Stem Cell Market

26 November 2019: Stem cells are undifferentiated cells which can multiply into several other types of cells and also into same type of stem cells. There are two forms of stem cells- embryonic stem cells and adult stem cells. Embryonic stem cells, as the name suggests, are isolated during the early embryonic phase whereas adult stem cells are isolated from fully grown individuals. Stem cells are being studied by researchers all over the world for their unique regenerative characteristics and applications in medicine.

Cell Acquisition Technology Segment to Contribute Significant Demand to the Market

The major technology variants of the stem cell market include cell production (in-vitro fertilization, isolation, therapeutic cloning, and cell culture), cell acquisition (apheresis, bone marrow harvest, and umbilical blood cord), expansion and sub-culture, and cryopreservation. 

The cell acquisition sector accounted for the largest share in the stem cell industry and is anticipated to expand at the fastest CAGR in the forthcoming period. It is driven by rising consciousness regarding the importance and applicability of stem cells. Usually, bone marrow technology is used for cell acquisition on account of comparatively quicker production of new cells from bone marrow. Furthermore, cells that derive from bone marrow are more concentrated as compared to other origins.

The cell production segment accounted for a substantial share on account of increasing need from several clinical applications and ongoing technological advancements. On the basis of steps, the segment is classified into in-vitro fertilization, therapeutic cloning, isolation, and cell culture. The increasing number of organ replacement methods along with the demand for therapeutic has stimulated the sector development. 

Market Insights: 

Establishments are selecting multidisciplinary business expansion and multi-sector associations to ensure a constant supply of high quality differentiated and pluripotent cells. This is set to strengthen the competition, driving the need to launch innovative products continuously.

Becton Dickinson Biosciences is a world leader in bringing innovative research and diagnostic tools to laboratory professionals, life science researchers, clinical researchers, clinicians, and laboratory researchers. They are involved in drug discovery and development, basic research, disease management, and biopharmaceutical production. 

Leading players operating in the stem cell market include STEMCELL Technologies Inc.; Celgene Corporation; Osiris Therapeutics Inc.; Advanced Cell Technology Inc.; BIOTIME, INC.; Cytori Therapeutics; Human Longevity Inc.; Cynata; Promethera Biosciences; and Mesoblast.

Novel Technologies Fuels Optogenetics Actuators and Sensors

8th Aug 2019: Optogenetics is a procedure that uses light to modulate molecular procedures in a targeted way in the living organisms or cells. It depends on the practice of genetically-encoded proteins that alter conformation in the presence of light to change cell performance, for instance, by altering the membrane voltage potential of excitable cells.

Sensors to Develop as the Fastest Growing Segment in this Market 

On the basis of product type, optogenetics actuators and sensors can be classified into Actuators (Archaerhodopsin, Halorhodopsin, and Channel rhodopsin) and Sensors (Voltage-Sensitive Fluorescent Proteins, pH Sensors, and Genetically Encoded Calcium Indicators). Sensors segment is estimated to develop as the fastest growing sector in this market. 

Key investments by manufacturing entities for developments in voltage-sensitive fluorescent proteins, pH sensors, and genetically encoded calcium indicators are estimated to boost sector growth in the years to come. 

The voltage-sensitive, fluorescent protein-based sensors are developed by researchers that offer dynamic voltage reports. In addition, to improve fast fluorescent protein voltage sensors several continuous studies are being performed. 

Additionally, companies are launching and developing screening systems and optogenetic tools for behavioral testing of rodent models in studies relating to neuroscience. These products could be further used to progress potential and novel remedy for neurological difficulties such as autism spectrum syndrome.

Market insights:

Presently, some of the key players are collaborating with other companies and institutions to improve their product portfolios and develop novel optogenetic devices and therapies that can possibly restore neurological and retinal functions. Companies are also expanding their management facilities and R&D in order to develop their business services and hold a modest edge in the market. 

Leading players operating in the optogenetics actuators and sensors market include Gensight Biologics; Elliot Scientific Ltd.; The Jackson Laboratory; Add gene; Coherent, Inc.; Thorlabs, Inc.; Scientifica (Judges Scientific Plc Company); Bruker; Noldus Information Technology; Danaher; Prizmatix; Merck KGaA; AGTC; Circuit Therapeutics, Inc; and Shanghai Laser & Optics Century Co., Ltd. (SLOC).

Drug Discovery Fuels Demand for Nucleic Acid Isolation and Purification

Nucleic acid isolation and purification is a process of molecular biology that includes sequencing, polymerase chain reaction, cloning, etc. These procedures have numerous applications in the arena of life science research, genetic engineering, and molecular and forensic diagnostics. The processing of more samples in small time, reduces nucleic acid loss ad degradation and improves laboratory effectiveness and efficiency. 

Major Type Segment to Contribute Substantial Demand to the Market

The major type variants in the market include DNA (Viral DNA, Plasmid DNA, Genomic DNA, etc.) and RNA (mRNA, miRNA, Total RNA etc.). Over the years, researchers have succeeded in purifying and separating nucleic moieties such as miRNA, mRNA, genomic DNA and plasmid DNA. 

This supports in understanding diseases and their pathologies at a genomic level in detail, which in turn, has proven to be helpful in designing diagnostics and therapeutics for numerous diseases. The disengagement, detachment, purification, and ligation of nucleic acids have become a lot simpler than earlier, thanks to the growing use of RNA/DNA sequencing and technological advancements.

The DNA type segment accounted for the largest share in the market and will continue its dominance over the forthcoming period. The growth of the market is attributed to high demand from research laboratories which will drive the demand in the years to come. The DNA type segment will be followed by RNA segment throughout the forecast period. 

Market Insights

The Nucleic Acid Isolation and Purification Market is estimated to grow significantly throughout the forthcoming period thanks to reducing prices of genomic sequencing, companion diagnostics, ongoing development of personalized medicine, and technical developments in methods used for purification and isolation of nucleic acids. Companies are also involved in strategic contracts with global firms to increase their proteomics and genomics businesses. 

Leading players operating in the nucleic acid isolation and purification market include Danaher; Qiagen; Roche; Illumina, Inc.; Agilent Technologies; Promega Corporation; and Thermo Fisher Scientific, Inc. These companies have been developing at a fast pace due to significant tie-ups with medical device-, IT-, and healthcare- establishments.

Innovations in Microfluidics Prototype to Spur its Commercial Growth

Microfluidics is an emerging field presenting a remarkable potential for numerous applications, such as analytics, drug development, education, point-of-care diagnostics, organ-on-a-chip, research and development, chemical synthesis, and biomedical assays. 

There is a definite need for enhancing the present solutions for the manufacturing of microfluidics tools with more efficiency to be used for applications. Prototyping is an important step in product development used by companies. It helps the developers and designers to create partial product implementations.

Regional Insights:

North America is expected to be the largest market owing to the introduction of better-quality sample volume screening techniques, accessibility of high funding, and high research capital. U.S. is expected maintain the highest market share in the region owing to developed economies and technological advancement.

The Europe market is anticipated to exhibit a high CAGR over the forthcoming period since England plays a significant role owing to the increasing technical innovations. Asia Pacific is the fastest growing market due to the emerging economy, low labor cost, and developing research infrastructure. Global companies are trying to saturate untapped markets by presenting their products in the APAC region. 

Market Insights

uFluidix manufactures offer prototyping facilities of microfluidics devices and delivers grants for advanced startups and technologies in the initial prototype growth stage. It has integrated with a community named as the Microfluidic Circle, which inspires inventions and technological progressions in the arena. 

In May 2018, the company approved USD 50,000 worth of fabrication and design services to uFraction8 Ltd., a producer of microfluidic-based filtration schemes. Some manufacturers are starting alliances to transport advanced quality solutions to customers. For example, in July 2017, Aline, Inc. declared a planned corporation with Triple Ring Technologies (TRT) to offer diagnostic solutions in situations where microfluidic consumables are maintained with instrument automation.

Leading players operating in the microfluidics prototype market include thinXXS Microtechnology; micro LIQUID; Potomac; ALine, Inc.; Alvéole; uFluidix; Micronics, Inc.; and research groups from several universities. These key manufacturers also emphasize on numerous other business strategies, such as product developments, partnerships, technical collaborations, agreements, and capacity expansions to support their market place.

Stem Cells in Regenerative Medicine and Drug Discovery and Development

SAN FRANCISCO, November 22, 2018

A stem cell is a cell that holds an ability to provide new cells for the body as it nurtures and replace specific cells that are damage or lost. These cells are broadly categorized into human embryonic stem cells, adult Stem Cells, induced pluripotent stem cells, and very small embryonic like stem cells.

Stems cells can be developed in laboratory by taking a sample of adult cells such as blood cells or skin cells. For instance, the induced pluripotent stem cells (iPSCs) are developed in laboratory.

Effectiveness in Treating Diseases to Boost Demand 

Stem cells finds application in regenerative Medicine and drug discovery and development. Regenerative medicines are Regenerative medicine is observed to have high potential to treat degenerative ailments and traumatic injury. These medicines can be applicable in different condition including oncology, orthopedics, neurology, cardiovascular and myocardial Infraction, hematology, incontinence, liver disorder, diabetes, injuries, and others. The neurology holds the largest revenue share due to accessibility of FDA approved products. On other hand, oncology segment is likely to exhibit fastest growth due to presence of strong pipeline of cancer therapies. Many research institutes and universities are also taking efforts towards the study and development of regenerative medicines. For instance, The University of Florida has recently introduced a Center for Regenerative Medicine for developing lifesaving therapies.

Also, Elevian, a new company developing medicines to treat and prevent age-related disease launches at TechCrunch Disrupt's Startup Battlefield. The company is currently focusing on conditions such as coronary artery disease, type2 diabetes, Sarcopenia (age-related muscle dysfunction), and Alzheimer's diseases. 

Furthermore, use of stem cells in the development of novel drugs are expected to provide several new avenues for pharmaceutical companies. Developing trust of drug developing firms on cellular systems is expected to boost the drug discovery and development initiatives in the coming years.

Market Overview

According to a report published by Grand View Research, Inc.; the global stem cells market is expected to accomplish a valuation of around USD 15.63 billion by 2025. Increasing scope of these cells in clinical applications can drive the market during the forecast period (2014 to 2025). Technological advancements and growing research activities related to human stem cells is also expected to boost the market growth. Development of SCs for study of disease management is likely to increase the production of regenerative medicine. This is likely to support the market growth.

North America is expected to grow on account of existence of well-defined business models in the U.S. and Canada. On other hand, Asia Pacific is projected to display fastest growth over the forecast period.

Some of the leading companies operating in the stem cells market include Cellular Engineering Technologies Inc.; BrainStorm Cell Therapeutics; Bioheart Inc.; Advanced Cell Technology Inc.; and PromoCell GmbH.

NGS-based Targeted DNA/RNA Sequencing to Emerge Preferred Tool in Genome Projects

In recent times, targeted DNA/RNA sequencing has gained the global recognition as a key technology in research activities in the field of life science. It allows assessment of specific region of interest while maintaining complexity of data and sequence cost under manageable limits. Whole Genome and Exome Sequencing (WGS/WES) provides information on the whole sequence, however, it consumes time and requires high capital. Owing to its high flexibility and economic benefits, targeted sequencing is gaining preference in WGS/WES.

Sanger Sequencing to Lose Shares to NGS Technology

On the basis of technology, targeted DNA/RNA sequencing can be classified into Next-Generation Sequencing (NGS) and others, including Sanger sequencing. Demand for NGS-based methods will remain higher than their counterparts through 2025. The presence of a large number of high-throughput sequencers for examining mutations in a specific region of a genome is contributing to their demand. They allow screening hundreds to thousands of genes at a relatively lower cost, which is likely to supplement the segment growth. High success rate of the NGS technology is further boosting its adoption in new genome projects.

To put this in perspective, recently, Fusion Genomics announced that they are developing an assay, OneTest PathoGenome that can be used for diagnosis of infectious diseases. The assay is being developed using a combination of DNA/RNA capture probes, universal sample prep, and NGS. Besides this, increasing investments in the advancements of NGS technology will support the segment development. The NGS technology is expected to make inroads in the shares of Sanger sequencing, owing to its higher scalability and sensitivity as compared to the latter. Nevertheless, wherever workflow is concerned, Sanger method edges over second-generation sequencing methods.

Market Insights

As per the findings of Grand View Research Inc., the global targeted DNA/RNA sequencing market is estimated to rise to a valuation of USD 15.9 billion by 2025. Increasing R&D activities, to demonstrate a considerable reduction in the cost per sample by sequencing, is likely to work in favor of the market. Technological advancements in targeted DNA/RNA sequencing to standardize and simplify the sequence processes and cut down presequencing time is anticipated to play a pivotal role in the development of this market.

North America will hold a prominent position in the market throughout the forecast period (from 2018 to 2025). Presence of a significant number of genome centers along with favorable regulatory scenario is propelling the regional market. Some of the key companies in the market are F. Hoffmann-La Roche Ltd; Bio-Rad Laboratories, Inc.; Illumina, Inc.; Thermo Fisher Scientific, Inc.; and Agilent Technologies.

Read More @

https://www.grandviewresearch.com/industry-analysis/targeted-dna-rna-sequencing-market

Regeneration of Human Cells is Possible with Regenerative Medicine

Regenerative medicine is the branch of translational research in tissue engineering and molecular biology, which develops the procedure of repair, replacement, and regeneration of the damaged cells, organs, and tissues.

These medicines comprise tissue engineering, regeneration and use of therapeutic steam cells, and development of artificial organs. It finds applications in the treatment of orthopedic, dermatology, cardiovascular, and neurodegenerative disorders. This branch of medicine also involves study of genes, biologics, and stem cells.

Tissue Engineering

In tissue engineering, biologically compatible scaffolds are implanted at a specific part of the body to form a new tissue. Stem cells have the capability to develop themselves into diverse cell types in the body and also help as an internal repair system in many tissues. Stem cells are unspecialized cells and they have the ability to renew themselves via cell division. Moreover, under certain experimental or physiologic circumstances, they could develop into tissue or organ-specific cells with special functions. For example, in some organs like bone marrow, stem cells repeatedly repair and replace the damaged tissues. They also provide possibilities of treating chronic diseases including heart disease and diabetes.

Achilles Tendonitis Pain Management

In September 2017, MiMedx declared that the company has received an approval from the United States Food and Drug Administration (FDA) enabling them to proceed with the phase 3 clinical study of “Achilles Tendonitis” for Investigational New Drug (IND). 

Primary objective of this study is to determine the safe use of AmnioFix Injectable for treating severe Achilles Tendonitis. AmnioFix is a composite amniotic tissue membrane applicable to preserve the collagen matrix. This regenerative medicine can reduce the development of scar tissue and can boost the healing process. It can be utilized in soft tissue, tendon, and nerve applications.

Market Overview

According to Grand View Research, Inc.; the global regenerative medicine market is projected to achieve around USD 5.5 billion by 2025. High prevalence of genetic, neurodegenerative, and orthopedic diseases is one of the major market drivers. Impressive advancements in biotechnology may further impel the expansion over the forecast period (2014 to 2025). Introduction of policy reforms is also expected to create positive influence on the overall market growth.

Some of the leading companies in the market are AstraZeneca;Integra LifeSciences Corporation; F. Hoffmann-La Roche Ltd;Pfizer Inc; Baxter, and MiMedx Group, Inc.

To get free sample report at:

https://www.grandviewresearch.com/industry-analysis/regenerative-medicine-market/request

DNA Sequencing Becomes Easy with Molecular Biology Enzymes and Kits & Reagents

Molecular biology deals with the structure and function of biological phenomenon at the molecular level. It studies macromolecules using advanced tools and techniques. It requires a high purity substances and reagents to obtain accurate results.

Novel Developments

Molecular biology is used in cloning, life science research, diagnostic testing, restriction digestion, synthetic biology, drug discovery, and biotechnological research. Sequencing, epigenics, synthetic biology, and polymerase chain reaction (PCR), are some of the major applications of molecular biology enzymes and kits and reagents.

Epigenics and sequencing techniques are extensively used for cancer diagnosis and therapy. Synthetic biology is used for the development of biological products Polymerase chain reaction (PCR), also called molecular photocopying is a quick and cost-efficient technique used to amplify small segments of DNA. It includes, reverse transcription polymerase chain reaction (RT-PCR), also referred as known as quantitative polymerase chain reaction (qPCR).

Ultra-sensitive Detection Technique 

In June 2017, BIOTECON Diagnostics launched a new ‘lyophilized foodproof real-time PCR-test’. This test can find all kinds of species of Cronobacter within 24 hours. Cronobacter is a severe human pathogen with a high death rate. These organisms could pose a serious threat to the newborns as they are often found in infant food. The test kit has been authenticated with all appropriate food groups, including infant formulation such as skim milk powder, probiotics, and various environmental samples.

Market Overview

According to Grand View Research, Inc.; the worldwide molecular biology enzymes and kits & reagents market may attain over USD 26.7 billion by 2025. The growing biotechnology and pharmaceutical industry in developing countries can impel the growth over the forecast period (2014 to 2025).

Kits and reagents segment may continue dominating the overall market in terms of revenue over the forecast period owing to their low costs and frequent use in everyday procedures. The growth of synthetic biology is accredited to reduced cost of DNA sequencing and high demand for drugs, vaccines, and genetically modified biofuels.

North America held the major market share on account of revenue in 2016. Growing pharmaceutical industry in the US and intensifying research activities are the key regional drivers. Prominent players operating in the worldwide market include Thermo Fisher Scientific Inc.; Illumina Inc.; Merck KGaA; New England Biolabs; and QIAGEN.

To get free sample report at:

http://www.grandviewresearch.com/industry-analysis/molecular-biology-enzymes-kits-reagents-market/request